Searching for a cure, Improving lives

Aims and Objectives

Where did we come from?  Started as Parent Project UK, our founders (Janet and Nick) laid out our vision:

 To be a leader in supporting innovative research to cure and treat Duchenne.

 To work as a partner with organisations providing resources to help to improve the length and Quality of Life of those living with Duchenne.

 To be led by parents and young people affected by Duchenne and Becker Muscular Dystrophy.

 This has evolved into four areas within which Action Duchenne now focuses:

Cure: To change Duchenne into a treatable and manageable condition by producing, and delivering, a broad research strategy that seeks to find the cure or treatment for Duchenne or Becker  muscular dystrophy.

Influence:  To inform political debate in the fight to improve the quality of life for those living with Duchenne or Becker muscular dystrophy by changing attitudes in standards of care, healthcare professionals and to influence the bench to bed times for treatments for those suffering with rare conditions.

Empower:   To continue to provide education for those living with duchenne/beckers muscular dystrophy through Decipha and Takin’ Charge by: continuing to fund Decipha to provide specialist learning assessments and interventions to support young people , their families and schools and to increase attendance at the International Conference.

Improve:   To make the DMD registry as the database of choice for pharma and clinicians by increasing the numbers of those registering on the database and to increase revenue from it.

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Summit presents data from Phase 1 clinical programme of lead utrophin modulator, ezutromid

June 22nd, 2017

Summit Therapeutics has today announced the presentation of clinical data from two Phase 1 clinical trials

Tell me more

What Raxone being given approval through the EAMS scheme means for the Duchenne community

June 22nd, 2017

  Over a number of years we have worked closely with Santhera Pharmaceuticals and other

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne